Avid Bioservices (CDMO)
(Delayed Data from NSDQ)
$9.39 USD
+0.04 (0.43%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $9.38 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
Avid Bioservices, Inc. [CDMO]
Reports for Purchase
Showing records 1 - 20 ( 62 total )
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Starts to Address Investor Concerns
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for CDMO 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 - Expansions Under Way, Compelling Setup on Biological Production
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 - Exceeds Quarter, Tepid Guidance but Strong Order Trend
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 - Robust Biological Success and Upgrade to Overweight
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Model Update to Reflect CAPEX and Peer Comments
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Life Science Technology - Biologic Transformation Continues - 2023 Outlook
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 - FY23 Guidance Raised, Bookings Light but Positive Indicators
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Indicates Strong Biological Production Demand in 2022
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Robust Bioprocess Pipeline Shown in 4Q (April) Results
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
Company: Avid Bioservices, Inc.
Industry: Medical - Biomedical and Genetics
2022 Life Sciences and MedTech Conference: Day 2 Takeaways
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department